USFDA inspection: Biocon Biologics gets 8 observations for Malaysia insulin facility

Bengaluru: Biocon Biologics has announced that the U.S. Food and Drug Administration (FDA) conducted two cGMP inspections at Biocon Sdn. Bhd’s Insulins Manufacturing Facility in Malaysia, encompassing Biologics Drug Substance, Drug Product units and Quality Control laboratories, as well as the Delivery Devices unit.

These inspections were conducted between July 10 and July 20, 2023.

At the conclusion of these inspections, the agency issued a Form 483 with 6 observations for Drug Substance, Drug Product units and Quality Control laboratories as well as 2 observations for the Delivery Devices unit.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Read also: Biocon Biologics Bengaluru facility gets EU GMP certification for Bevacizumab

These observations primarily relate to enhancing operational procedures and strengthening training programs. The inspections did not identify any data integrity breaches or systemic non-compliance.

"We will submit a Corrective and Preventive Action (CAPA) plan to the U.S. FDA in a timely manner and are confident of addressing these observations expeditiously. Biocon Biologics remains committed to global standards of Quality and Compliance.” the company's spokesperson said in a statement.